Clinical Trial Update: A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy of secukinumab 300 mg in Chinese adults with active ankylosing spondylitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Tongji Hospital | Conditions: Ankylosing Spondylitis (AS) | Phase 4 | Status: RECRUITING